Positive outcome of first-line therapy for a SMARCA4-deficient thoracic sarcomatoid tumor
Author:
Publisher
Springer Science and Business Media LLC
Link
http://link.springer.com/content/pdf/10.1007/s13691-021-00472-4.pdf
Reference10 articles.
1. Wilson BG, Roberts CW (2011) SWI/SNF nucleosome remodelers and cancer. Nat Rev Cancer 11:481–492
2. Schneppenheim R, Fruhwald MC, Gesk S et al (2010) Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome. Am J Hum Genet 86:279–284
3. Witkowski L, Carrot-Zhang J, Albrecht S et al (2014) Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type. Nat Genet 46:438–443
4. Le Loarer F, Watson S, Pierron G et al (2015) SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related BAF-deficient sarcomas. Nat Genet 47:1200–1205
5. Rekhtman N, Montecalvo J, Chang JC et al (2020) SMARCA4-deficient thoracic sarcomatoid tumors represent primary smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas. J Thorac Oncol 15:231–247
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Thoracic SMARCA4-deficient undifferentiated tumor: A clinicopathological and prognostic analysis of 35 cases and immunotherapy efficacy;Lung Cancer;2024-03
2. Thoracic SMARCA4-deficient tumors: a clinicopathological analysis of 52 cases with SMARCA4-deficient non-small cell lung cancer and 20 cases with thoracic SMARCA4-deficient undifferentiated tumor;PeerJ;2024-02-16
3. The golden key to open mystery boxes of SMARCA4-deficient undifferentiated thoracic tumor: focusing immunotherapy, tumor microenvironment and epigenetic regulation;Cancer Gene Therapy;2024-02-13
4. Chemotherapy and Immune Checkpoint Inhibitors in a Case of SMARCA4-dUT: A Case Report and Review of Literature;Journal of Investigative Medicine High Impact Case Reports;2023-01
5. A case of thoracic SMARCA4 ‐Deficient undifferentiated tumor successfully treated with combination Ipilimumab–Nivolumab;Clinical Case Reports;2022-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3